Key Highlights
- The February Reverse Morris Trust roughly doubled Waters' Revenue base to a guided $6.405–$6.455 billion for 2026, but cost 39.2% of the Equity and added $4 billion of Debt .
- First-quarter adjusted EPS of $2.70 beat expectations and full-year guidance was raised to $14.40–$14.60, while GAAP results showed a $0.87 loss per share on Acquisition accounting.
- At roughly 26 times guided 2026 adjusted EPS and 6.6 times Enterprise value to guided revenue, the shares are priced for competent integration rather than for synergy upside.
- At last closing, Waters completed its combination with Becton Dickinson's Biosciences and Diagnostic Solutions Business , a transaction announced in July 2025 at an implied value of roughly $17.5 billion.
The deal that changed the company
At last closing, Waters (NYSE:WAT) completed its combination with Becton Dickinson's Biosciences and Diagnostic Solutions business, a transaction announced in July 2025 at an implied value of roughly $17.5 billion. The structure was a Reverse Morris Trust: BD separated the unit into a vehicle named Augusta SpinCo, distributed its shares to BD holders of record on 5 February, then merged it into Waters. Each SpinCo share converted into 0.135343148384084 Waters shares, 38,541,851 new shares in total, leaving former BD shareholders with about 39.2% of Waters and legacy holders with 60.8%.
The cash leg matters as much as the equity. SpinCo borrowed $4.0 billion of unsecured term loans on 6 February, split between $3.5 billion maturing in 364 days and $500 million due in two years, and paid the full $4.0 billion to BD ahead of the distribution. Waters guaranteed the obligations. BD said it would direct $2 billion of that toward an accelerated share repurchase and $2 billion toward debt repayment. Waters, which carried $1.4 billion of total debt at the end of 2025, finished the first quarter with $5.2 billion.
Price action has not tracked the revenue jump
The shares closed at $377.31, down 0.79% on the day, against a 52-week range of $275.05 to $414.15 and a market Capitalization of $37.05 billion. The stock is up about 26% over the past year, respectable, but short of the doubling in revenue base the Merger delivered. July trading was choppy without direction, bottoming at $357.54 on 20 July and peaking at $383.90 on 28 July.
Investors were handed 39% share-count dilution and $4 billion of new debt in exchange for a business Waters expects to contribute about $3.0 billion of revenue in 2026. The market has so far treated that as a wash pending evidence.
What Waters now sells
The pre-deal company was a high-quality but slow-growing Franchise built on liquid chromatography, mass spectrometry and the TA Instruments thermal analysis line, selling into pharmaceutical quality control, industrial testing and academic labs. About half of revenue was recurring, service contracts, columns and chemistry consumables attached to a large installed base, which cushioned it through instrument-capex downturns.
The acquired Assets change the mix rather than the model. Waters now reports four divisions: Analytical Sciences (the legacy instruments core), Materials Sciences (TA), Biosciences (flow cytometry and reagents) and Advanced Diagnostics (BD's Diagnostic Solutions microbiology and specimen-management franchise plus Waters' own clinical unit). Management's argument is that both acquired businesses are consumables- and reagent-heavy, tilting the group further toward Annuity revenue, and that Waters' commercial machinery can lift growth rates that had stalled inside BD. The July 2025 announcement put combined 2025 pro forma revenue near $6.5 billion, adjusted EBITDA near $2.0 billion, and the addressable market at roughly $40 billion.
First quarter with the new assets
The quarter ended captured under two months of ownership and still produced revenue of $1.267 billion, up 91%. Legacy Waters grew 13% reported and 11% in constant currency to $747 million. Analytical Sciences rose 14% to $607 million and Materials Sciences 6% to $79 million; Biosciences contributed $232 million and Advanced Diagnostics $349 million on an owned-period basis. Service revenue reached $348 million, up 33% and about 27% of the total. By region, the Americas grew 98% to $505 million, Europe 122% to $412 million and Asia 58% to $350 million; the release did not break out China separately, so the China recovery question remains unresolved from disclosure alone.
The two Earnings lines tell opposite stories, and both are real. On a GAAP basis Waters posted an operating loss of $47 million and a diluted loss of $0.87 per share, driven by $152 million of purchased-intangible amortization against $12 million a year earlier, plus inventory step-up and deal costs. Adjusted EPS was $2.70, up 20% and ahead of the roughly $2.31 consensus, with adjusted Operating Margin of 23.6%. Cash Flow was the weak spot: Operating Cash Flow of negative $3 million and adjusted free cash flow of negative $42 million, reflecting transaction outflows. The Balance Sheet now carries $9.3 billion of Goodwill and $8.8 billion of intangibles against $24.5 billion of total assets.
Management raised full-year adjusted EPS guidance to $14.40–$14.60 from $14.30–$14.50, with revenue of $6.405–$6.455 billion and organic constant-currency growth of 6.5%–8.0%. Second-quarter guidance is $1.616–$1.631 billion of revenue and $2.95–$3.05 of adjusted EPS.
The bull argument rests on synergy arithmetic
Waters has targeted $200 million of cost synergies by year three and $290 million of revenue synergies by year five, totaling roughly $345 million of annualized EBITDA benefit by 2030, with about $50 million of revenue synergies expected in 2026 alone. Against roughly $2.0 billion of pro forma EBITDA, that is worth real value on its own. Chief executive Udit Batra told investors the Biosciences and Advanced Diagnostics divisions were "off to a strong start with a significant improvement in growth rates versus pre-close trends", the most important claim in the release, because those assets were growing slowly under BD.
The bear argument rests on execution and Leverage
Nothing here is de-risked. Waters must refinance $3.5 billion of 364-day paper within a year, and interest expense now sits against a company whose free cash flow was negative in the first quarter. Purchased-intangible amortization of roughly $150 million a quarter will keep GAAP earnings depressed for years, forcing investors to underwrite adjusted numbers. Integrating a diagnostics business with different customers, regulatory pathways and reimbursement dynamics is a different skill from selling chromatography systems. Pharma instrument capex remains cyclical, and Waters flags tariffs as a risk without quantifying the exposure.
What the market is paying
At $377.31 the shares trade near 26 times the midpoint of 2026 adjusted EPS guidance, close to the 25.1x forward multiple cited by data providers. Trailing multiples are not usable: the 54.8x trailing P/E, 9.8x price-to-sales and 11.2x EV/sales all reflect a revenue base that includes less than two months of the acquired business. On the $42.19 billion enterprise value against guided 2026 revenue of about $6.43 billion, the stock is nearer 6.6 times sales, a normal life-science-tools multiple, not a premium one. Consensus among 24–25 analysts is a Buy with an average target around $413, spanning $349 to $460.
Whether the stock catches up turns on delivery, not sentiment: two or three quarters of the acquired divisions growing mid-single digits or better, cash conversion normalizing, and the 364-day Loan refinanced on reasonable terms. Second-quarter results are the first clean look at the combined company.
Upcoming Catalysts
- Q2 2026 results, scheduled. The first full quarter with all four divisions consolidated; watch acquired-division organic growth and whether free cash flow turns positive.
- Refinancing of the $3.5 billion 364-day term loan, by early February 2027. Terms will set the interest-expense run rate and test the balance sheet.
- Full-year 2026 close and 2027 guidance, expected February 2027. The first framing of year-two cost synergies against the $200 million three-year target.
- Progress on the ~$50 million of 2026 revenue synergies. Management has tied these to replacement-cycle selling, E-commerce and service attachment across the acquired base.
Principal Risks
- Integration execution. Combining a diagnostics and flow-cytometry business with an instruments franchise involves different customers, regulatory regimes and channel Economics ; slippage would undercut the entire deal thesis.
- Leverage and refinancing. Total debt rose to $5.2 billion, including $3.5 billion maturing within 364 days of the February drawdown, against negative adjusted free cash flow in the first quarter.
- Dilution and GAAP earnings quality. The 38.5 million shares issued permanently dilute legacy holders, and roughly $150 million of quarterly intangible amortization will keep GAAP results well below adjusted figures.
- End-market cyclicality. Pharmaceutical instrument capex, academic and government funding, and China Demand all remain volatile, and Waters did not break out China performance in its first-quarter release.
- Tariffs and trade policy. Waters lists Tariff exposure among its forward-looking risks without quantifying the potential cost impact.
Conclusion
The February Reverse Morris Trust roughly doubled Waters' revenue base to a guided $6.405–$6.455 billion for 2026, but cost 39.2% of the equity and added $4 billion of debt. Set against that: Combining a diagnostics and flow-cytometry business with an instruments franchise involves different customers, regulatory regimes and channel economics; slippage would undercut the entire deal thesis. That tension shows up in the valuation: At roughly 26 times guided 2026 adjusted EPS and 6.6 times enterprise value to guided revenue, the shares are priced for competent integration rather than for synergy upside. The next real test: The first full quarter with all four divisions consolidated; watch acquired-division organic growth and whether free cash flow turns positive.
This article is for informational purposes only and does not constitute Investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.






Please wait processing your request...